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Background: Korean Red Ginseng (Panax ginseng) has been shown to exert antihypertensive
effects. In particular, ginsenoside Rg3 is thought to be a potent modulator of vascular func-
tion. The present study was performed to examine the antihypertensive efﬁcacy of Korean
Red  Ginseng (KRG) extract and Rg3-enriched KRG (REKRG) extract.
Methods: Spontaneously hypertensive rats (SHRs) and Wistar–Kyoto rats (WKYs) were divided
into  six groups (WKY control, WKY-KRG, WKY-REKRG, SHR control, SHR-KRG, and SHR-
REKRG), and systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured
at  the carotid artery, followed by injection of 3 mg/kg KRG or 3 mg/kg REKRG.
Results: REKRG treatment signiﬁcantly decreased SBP and DBP 3 hours post-treatment in the
SHR group compared with SHR control group. However, SBP and DBP were not signiﬁcantly
different in KRG-treated SHRs compared with control SHRs. REKRG treatment did not sig-
niﬁcantly alter SBP or DBP 3 hours post-treatment in the WKY  group compared with WKY
control group. Similarly, there were no differences in SBP or DBP with KRG treatment in
the  WKY group and WKY control group. Both KRG and REKRG increased endothelial nitric
oxide synthase phosphorylation levels in the aorta, and the increases in endothelial nitric
oxide synthase phosphorylation levels by REKRG treatment were higher than those with
KRG treatment. Similarly, nitric oxide production in plasma from WKYs and SHRs was also
increased by both KRG and REKRG.Conclusion: These results suggest that REKRG has a more beneﬁcial effect on blood pressure
control than KRG in SHRs.
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1.  Introduction
Korean Red Ginseng (Panax ginseng) is a traditional Korean
tonic medicine known for its efﬁcacy in promoting physical
strength and immunity, which may ameliorate certain chronic
disease states such as vascular disease and hypertension.1
Ginsenosides as a biologically effective extract of P. ginseng
are a mixture of triterpene glycosides. The major fractions
of ginsenosides consist of two groups according to chemi-
cal structure: the panaxadiol group is represented by Rb1,
Rb2, Rb3, Rc, Rd, Rg3, Rh2, and Rs1, while the panaxatriol
group consists of Re, Rf, Rg1, Rg2, and Rh1. Ginsenosides
are well known to have hypotensive effects in experimen-
tal animals and hypertensive patients.2–4 Moreover, they
enhance cardiovascular functions associated with vasore-
laxation and stimulation of nitric oxide (NO) production
from endothelial NO synthase (eNOS).3,5 Recently, individ-
ual ginsenosides have been shown to have different effects
via various mechanisms in many  tissues. In addition, stud-
ies of vascular disease are focusing on puriﬁed individual
ginsenoside fractions from ginseng to identify the key com-
ponents instead of using mixed ginsenosides. Among the
ginsenosides of the panaxadiol and panaxatriol groups, gin-
senoside Rg3 is a potent vasodilator that has been shown to
provide vascular protective effects, such as antivascular con-
traction and antihypertensive effects as well as enhancement
of NO production and eNOS activity.2,6,7 Previously, we  also
showed that Rg3 improved vascular function through eNOS
activation.2
NO is a major endothelium-dependent relaxing factor, and
its production by vascular endothelial cells plays a critical
role in the regulation of vascular motor tone and stability
of blood ﬂow as well as blood pressure.8,9 NO is synthe-
sized by the vascular endothelial cells using l-arginine as a
substrate in a process catalyzed by NOS10 and induces vas-
cular smooth muscle relaxation by activation of guanylate
cyclase.11 Because it is an isoform of NOS that produces NO,
eNOS also plays an important role in regulating systemic blood
pressure.12 Previous studies have shown that a decrease in NO
production can lead to hypertension,13 and eNOS mutation
leads to impaired endothelium-dependent vasorelaxation and
may have hypertensive effects.14 In addition, blood pres-
sure was enhanced in rats in which eNOS was inhibited
with N-nitro-l-arginine methyl ester.15 Recent studies have
suggested that production of NO is reduced and endothelium-
dependent vasorelaxation is blunted in patients with essential
hypertension.16
Previous studies have shown the effects of P. ginseng on
vascular regulation and blood pressure control, and effects
of total ginsenosides and Rg3 on eNOS activation and NO
production. However, there is no previous study for compari-
son between KRG and Rg3-enriched KRG (REKRG). Therefore,
in this study, the efﬁcacy of total ginsenoside (KRG) and
REKRG was compared in Wistar–Kyoto rats (WKYs) and
spontaneously hypertensive rats (SHRs). We examined the
enhancement of blood pressure stability, eNOS phosphory-
lation and NO production by REKRG in SHRs compared with
WKYs.Integr Med Res ( 2 0 1 6 ) 223–229
2.  Methods
2.1.  Preparation  of  REKRG
Dried KRG (P. ginseng) root was purchased from Gumsan
Nonghyup (Gumsan, Korea). Korean ginseng was extracted
twice with 10 volumes of ethanol at 50 ◦C for 7 hours (1st
50%, 2nd 85%), and then concentrated under vacuum at 50 ◦C
as described previously.2 The crude extract was dissolved in
water, and enzyme–acid hydrolysis was performed to maxi-
mize ginsenoside Rg3 (raw ginsenoside was hydrolyzed to Rg3)
under acidic (pH 2.5–3.5) and thermophilic (65–80 ◦C) condi-
tions. The enzyme, which has -glycosidase activity including
cellulose, hemicellulose, and glucosidase activities, was pro-
duced by Aspergillus niger. To remove the acid solution and
concentrate Rg3, the reactant was passed through a column
packed with DIAION HP20 resin (Mitsubishi Chemical Indus-
tries, Tokyo, Japan). The ginsenoside Rg3, kindly provided
by BTGin Corporation (Occheon, Korea), was concentrated to
powder under vacuum.
2.2.  Animals  and  blood  pressure  measurements
Male 10–12-week-old SHRs and WKYs weighing 250–320 g
were purchased from Central Lab. Animal Inc. (Seoul, Korea).
SHRs and WKYs were randomly divided into six groups: WKY
control, WKY-KRG, WKY-REKRG, SHR control, SHR-KRG, and
SHR-REKRG, and systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured at the carotid artery for
3 hours, followed by jugular vein injection of 3 mg/kg KRG or
3 mg/kg REKRG, as described previously.17 Animals were raised
under conditions of controlled lighting (06:00–18:00 hours
daily) and temperature (24 ± 1 ◦C). Rats were anesthetized with
urethane (1,200 mg/kg), and the left common carotid artery
was cannulated with a cannula preﬁlled with heparinized nor-
mal  saline (0.5 IU/mL) to measure arterial blood pressure. The
arterial pressure was determined using a student physiogra-
phy/data system (ADInstruments, Dunedin, New Zealand) and
analyzed using Chart Pro software (ADInstruments). The jugu-
lar vein was cannulated for administration of saline as well as
REKRG or KRG.
2.3.  Western  blotting
Anti-phospho-eNOS antibody was purchased from Cell
Signaling (Beverly, MA, USA). Anti-NOS3 antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Western blotting analysis was performed by adding 30 g
tissue homogenate (obtained from rat aorta) to SDS–PAGE
loading buffer followed by boiling and separation by elec-
trophoresis and transfer onto nitrocellulose membranes.
After incubation with appropriate primary and peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology),Signal West Pico or Femto Substrate from Thermo Fisher
Scientiﬁc (Rockford, IL, USA). Blots were imaged and band den-
sities quantiﬁed with a Gel Doc 2000 Chemi Doc system using
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Fig. 1 – Acute effects of Rg3-enriched Korean Red Ginseng
extract (REKRG) on changes in blood pressure in
Wistar–Kyoto rats (WKYs). Korean Red Ginseng extract
(KRG) and REKRG were injected intravenously at 3 mg/kg,
and both systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were  measured in WKYs for 3 hours.
(A) KRG and REKRG did not signiﬁcantly alter SBP compared
with controls. (n = 6). (B) KRG and REKRG did not. Nagar et al/Effect of Korean Red Ginseng on hypertension 
uantity One software (Bio-Rad, Hercules, CA, USA). Values
ere normalized relative to -actin loading control.
.4.  Nitrite  and  nitrate  measurements
O metabolites nitrite (NO2−) and nitrate (NO3−), the stable
reakdown products of NO, were quantiﬁed using a com-
ercially available kit (Nitrate/nitrite Fluorometric Assay Kit;
ayman Chemicals, Lexington, KY, USA). Plasma obtained
rom rat blood was deproteinized using a 10-kDa cutoff ﬁlter
Microcon YM10; Millipore, Bedford, MA,  USA). After subtrac-
ion of background ﬂuorescence, values were normalized to
etermine the total protein level.
.5.  Statistical  analysis
ll experiments were performed at least three times. Statisti-
al analysis was performed using SPSS version 13.0 (SPSS Inc.,
hicago, IL, USA). Data are presented as the mean ± standard
eviation. Statistical signiﬁcance was determined by analy-
is of variance followed by the multiple comparison test with
onferroni adjustment. In all analyses, p < 0.05 was taken to
ndicate statistical signiﬁcance.
.  Results
.1.  REKRG  reduces  BP  of  SHRs
n our previous study, we  showed that the concentration of
insenoside Rg3 in REKRG is ∼300-fold higher than that in KRG,
nd that REKRG improves impaired endothelium-dependent
asorelaxation in the aorta in SHRs.2 In this study, we  exam-
ned the effects of REKRG or KRG treatment on SBP and DBP in
HRs and WKYs. For this, REKRG and KRG were injected into
he jugular vein of SHRs and WKYs at a dose of 3 mg/kg and the
lood pressure was recorded for 3 hours. Measurements were
aken at baseline and then at 30 minutes, 1 hour, 90 minutes,
 hours, 150 minutes, and 3 hours. Many  previous studies have
hown that ginsenosides reduce BP via increases in the pro-
uction of endothelial NO,7 and that Rg3 is the most potent
insenoside that activates eNOS in the rat aorta. As shown in
ig. 1, administration of both KRG and REKRG to WKYs caused
o changes in either SBP (Fig. 1A) or DBP (Fig. 1B) recorded from
 hours to 3 hours following treatment. By contrast, adminis-
ration of REKRG caused signiﬁcant decreases in both SBP and
BP in SHRs (Figs. 2A and 2B) starting as early as 30 minutes
ost-treatment of REKRG. However, both SBP and DBP were
naffected by administration of KRG in SHR.
.2.  REKRG  stimulates  phosphorylation  of  eNOS
NOS serves an important basal regulatory function in the
asculature. When subjected to stimuli, such as shear stress
r acetylcholine, eNOS constitutively expressed in endothe-
ial cells oxidizes l-arginine to generate l-citrulline and NO.
g3 is one of the major biologically active components of gin-
eng and is regarded as the main compound responsible for
ts many  pharmacological actions, including enhancementsigniﬁcantly alter DBP compared with controls. (n = 7).
of eNOS phosphorylation and NO production. We exam-
ined eNOS phosphorylation by western blotting analysis
of tissue homogenate from the aortas of both WKYs and
SHRs after administration of KRG or REKRG. As shown in
Fig. 3A, administration of both KRG and REKRG stimulated
Ser-1177 phosphorylation of eNOS in WKYs. Similarly, Ser-
1177 phosphorylation of eNOS was also increased in SHRs
after administration of KRG and REKRG (Fig. 3B), but the
overall level of phosphorylation was higher in SHRs than in
WKYs. In addition, the efﬁciency of REKRG to stimulate eNOS
phosphorylation was much higher than that of KRG in both
groups.
3.3.  REKRG  stimulates  production  of  NO
NO is an endothelium-derived relaxing factor that plays an
important role in the control of vascular tone and vascular
functions. The synthesis of NO by the vascular endothelium
is responsible for vasodilator tone, which is essential for the
regulation of BP. High BP is characterized by deﬁciency of
eNOS and decreased NO production, especially in the endothe-
lium. Therefore, we  measured the plasma levels of NO in
WKYs and SHRs after administration of KRG or REKRG. As
expected, administration of both KRG and REKRG stimulated
NO production in WKYs and SHRs (Figs. 4A and 4B). The
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Fig. 2 – Acute effects of Rg3-enriched Korean Red Ginseng
extract (REKRG) on changes in blood pressure in
spontaneously hypertensive rats (SHRs). Korean Red
Ginseng extract (KRG) and REKRG were  injected
intravenously at 3 mg/kg, and both systolic blood pressure
(SBP) and diastolic blood pressure (DBP) were  measured in
SHRs for 3 hours.
(A) REKRG signiﬁcantly decreased SBP compared with
controls. However, KRG did not. (B) REKRG signiﬁcantly
decreased DBP compared with controls. However, KRG did
not.
Data are presented as mean ± standard deviation
(n = 6 or n = 7).
* p < 0.05 compared with control.
efﬁciency of REKRG to stimulate NO production was higher
than that of KRG in both groups. These results suggest that
REKRG stimulates the eNOS signaling pathway, leading to its
phosphorylation, which in turn leads to an increase in NO
production in SHR.
4.  Discussion
High BP is one of the major risk factors for the development
of vascular diseases such as atherosclerosis, coronary heart
disease, and stroke,18 and several studies have reported car-
diovascular risks associated with elevated BP.19,20 High BP is
related to morphological changes and impaired function of
vascular smooth muscle and endothelial cells. The beneﬁ-
cial effects of ginsenosides have been widely studied and
shown to have new antihypertensive effects3 and prevent or
ameliorate various diseases, including atherosclerosis, can-
cer, and thrombosis.21–23 In this study, we  demonstrated that
REKRG increased eNOS phosphorylation and NO production
and decreased BP in SHRs. These results indicate that REKRGIntegr Med Res ( 2 0 1 6 ) 223–229
administration has the potential to stabilize BP and prevent
cardiovascular disease.
Several recent studies regarding cardiovascular disease
focused on puriﬁed individual ginsenoside components of
ginseng to show speciﬁc mechanisms instead of using
whole ginseng extracts. Various components of whole gin-
seng extracts (i.e., ginsenosides Rg3, Rb1, and Re) display
antihypertensive and cardiovascular protective effects.7,24
Therefore, they are considered potential components for vas-
cular protection. In particular, ginsenoside Rg3 has been
studied extensively because it is the most potent vasodilator
among the ginsenosides characterized to date. For exam-
ple, Rg3 induces endothelium-independent vasorelaxation
through inhibition of vascular smooth muscle tone by pre-
vention of Ca2+ inﬂux and stimulation of K+ efﬂux.7 Moreover,
it stimulates vascular-endothelium-derived NO and induces
vasodilation in the rat aorta.23,24 Another important factor is
that it can be easily extracted from red ginseng by a steaming
and drying process. Processed ginseng, which contains high
levels of Rg3, has emerged as a health-supporting agent in
some East Asian countries, including Korea and China. In this
study, we further investigated the vasoactive efﬁcacy of the
selected ginsenosides on vascular function and compared the
effects of ginsenosides to two major isolated fractions (KRG
and REKRG). In our previous study, we analyzed 11 ginseno-
sides (Rg1, Re, Rf, Rh1, Rg2, Rb1, Rc, Rb2, Rg3, Rk1, and Rg5) by
high-performance liquid chromatography.2 The REKRG frac-
tion was shown to contain Rg1, Re, Rf, Rh1, Rg2, Rb1, Rc, Rb2,
Rg3, Rk1, and Rg5 at levels of 0.6 mg/g, 1.9 mg/g, 12.3 mg/g,
5.0 mg/g, 4.2 mg/g, 3.8 mg/g, 1.2 mg/g, 1.0 mg/g, 100.0 mg/g,
12.0 mg/g, and 21.0 mg/g, respectively, while the levels in
KRG were 2.9 mg/g, 4.2 mg/g, 0.3 mg/g, 0.1 mg/g, 0.2 mg/g,
5.9 mg/g, 2.2 mg/g, 2.1 mg/g, 0.3 mg/g, 0.05 mg/g, and 0.12 mg/g,
respectively. These results indicate that the concentration
of ginsenoside Rg3 in REKRG is ∼300-fold greater than that
in KRG. We showed that REKRG improved endothelium-
dependent vasorelaxation in the WKYs and SHRs compared
with controls, and that REKRG treatment for 6 weeks reduced
the mean aortic intima–media thickness compared with con-
trols. The results of the present study also indicate that REKRG
stimulates endothelium-dependent vasorelaxation through
not only eNOS phosphorylation but also NO production.
Although REKRG did not signiﬁcantly decrease BP in WKYs,
it markedly decreased BP in SHRs. In addition, REKRG has
a greater antihypertensive effect than KRG at the same
dose even though KRG is known to have an effect on high
BP. Therefore, these data suggest that Rg3 is the princi-
pal pharmacologically active component of KRG and that it
could be an excellent candidate for use in antihypertensive
therapy.
One of the limitations of our study was that we  mea-
sured the BP of rats under anesthesia. It has been shown
previously that anesthesia itself can have an inﬂuence on car-
diovascular function.25 Anesthetic drug administration has
an effect on the autonomic nervous system, thus limiting
the evaluation of changes in BP. Therefore, in this study,
administration of KRG or REKRG to the rats under anesthesia
may have caused changes in parameters, such as heart rate,
resulting in tachycardia or bradycardia in anesthetized rats
as a compensation against hypotension by the decrease of
H. Nagar et al/Effect of Korean Red Ginseng on hypertension 227
Fig. 3 – Effects of Rg3-enriched Korean Red Ginseng extract (REKRG) on phosphorylation of endothelial nitric oxide synthase
(eNOS). The phosphorylation of eNOS was measured in the aorta 3 hours after intravenous injection of Korean Red Ginseng
extract (KRG) and REKRG 3 mg/kg.
(A) REKRG and KRG signiﬁcantly increased eNOS phosphorylation compared with saline control in Wistar Kyoto rat (WKY).
The levels of eNOS phosphorylation were  quantiﬁed by densitometrie analysis (lower panels). (B) REKRG and KRG
signiﬁcantly increased eNOS phosphorylation compared with saline control in spontaneously hypertensive rat (SHR). The
levels of eNOS phosphorylation were  quantiﬁed by densitometrie analysis (lower panels) western blots shown are
representative of three independent experiments.
Data are presented as mean ± standard deviation (n = 6 or n = 7).
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eripheral resistance.3 Similarly, KRG or REKRG administra-
ion may also cause a decrease in heart contractility directly
n anesthetized rats because rats under anesthesia may have
educed nervous reﬂex control and synaptic transmission in
he autonomic nervous system.
NO is a radical generated from l-arginine by NOS, which
10lays a critical role as a second messenger in cell signaling.
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ig. 4 – Effects of Rg3-enriched Korean Red Ginseng extract
REKRG) on nitric oxide (NO) production. Metabolites of NO
nitrite and nitrate) were  measured in the plasma of rats
 hours after intravenous injection of Korean Red Ginseng
xtract (KRG) and REKRG 3 mg/kg.
A) REKRG signiﬁcantly increased NO production compared
ith saline control in Wistar Kyoto rat (RAT). (B) REKRG
igniﬁcantly increased NO production compared with
aline control in spontaneously hypertensive rats (SHR).
ata are representative of three independent experiments
nd are presented as mean ± standard deviation.
 p < 0.05 compared with control.lar tone. Some biochemical stimuli, such as thrombin, ADP,
serotonin, acetylcholine, and bradykinin, as well as mechan-
ical stimuli including shear stress and cyclic strain, result
in increased synthesis of endothelial NO. Previous studies
have shown a relationship between NO and hypertension.
Inhibition of NO synthesis in the vasculature may lead to
hypertension or ischemic stroke, likely through its effects on
vascular tone. NO produced by vascular endothelial cells has
been implicated in many  of the effects of ginsenosides, includ-
ing those on vessel relaxation, protection of the cardiovascular
system, and antithrombotic and antiplatelet effects.23,26
Various factors can inhibit NO synthesis; one of which
is excessive production of reactive oxygen species (ROS)
by endothelial cells. ROS refers to oxygen radicals such as
superoxide anion, hydroxyl radical, hydrogen peroxide, and
peroxynitrite.27 Studies over the past decade have indicated
that ROS generated by endothelial cells play key roles in
the signaling mechanisms and affect vascular homeostasis.
Endothelial cells are not only major sources but also targets of
ROS. Among the various ROS species, the superoxide anion
destroys most of the NO28 and further increases oxidative
stress.29 The superoxide anion level has also been shown to be
increased in endothelial cells in SHRs,30 which scavenges NO
as soon as it is produced. Similarly, concentrations of superox-
ide anions produced by the aortic rings from SHRs were greater
than those produced by these structures from WKYs.31 Our
results were consistent with this observation and showed that
the level of NO production under basal conditions in WKYs
was higher than that in SHRs because increased ROS in SHRs
immediately destroyed endothelium-derived NO. Some pre-
vious reports have demonstrated the antihypertensive effect
of REKRG in human randomized control trials.32,33 Our results
demonstrate the antihypertensive effect of REKRG in compar-
r228  
ison to KRG in a rat model and we provide the mechanistic
pathway for its antihypertensive effect. We show that the
vasodilatory effect of REKRG is endothelium dependent, and
eNOS phosphorylation followed by NO production is the major
contributory factor to the observed vascular dilatation shown
in human trials.
In conclusion, the present results indicate that REKRG has
a signiﬁcant antihypertensive effect in SHRs, which may be
due to activation of eNOS and stimulation of NO production,
and that REKRG intake may be beneﬁcial for individuals with
high risks of hypertension and cardiovascular diseases.
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